drugset / Trial / NCT07166393
Valproic AcId for Traumatic BRAin INjury Trial
Phase 2/3
Not yet recruiting
432 enrolled
Northwestern University
United States Department of Defense · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI). Patients with moderate to severe TBI will randomly receive either: 1. Standard of care treatment and normal saline 2. Standard of care treatment and one dose of valproic acid (VPA) at a lower dose or a higher dose
Timeline
- Start
- 2026-05
- Primary completion
- 2030-02
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valproic Acid | Small molecule | 50 mg/kg | Intravenous |
| Subject | Valproic Acid | Small molecule | 100 mg/kg | Intravenous |